Editor's key points † Optimal management of massive transfusion (MT) requires coordination between clinical, laboratory, and haematology teams. † Early resuscitation using evidence-based MT protocols appears to improve outcome. † Close monitoring of metabolic and coagulation function is essential to prevent the lethal triad of hypothermia, acidosis, and coagulopathy in massively bleeding patients.
Management of patients requiring massive transfusion (MT) is challenging. Besides good clinical management and nursing care, it requires collaboration and effective communication between the clinical teams and the transfusion medicine service, which prepares and issues the blood products. Regardless of the aetiology of massive haemorrhage, the optimal strategy is to have a standardized management approach, such as an MT protocol (MTP), and to train the clinical and laboratory services potentially involved to be ready when a patient requires MT. MTPs should take into consideration not only transfusion of blood products, but use of laboratory tests, nursing care, and alternative therapies. This review focuses on the blood and blood-related transfusion management of patients requiring MTP. Most of the discussion below applies to trauma patients, as management of massive bleeding from other aetiologies follow the same general principles; potential differences are discussed where appropriate.
Definition of MT
MT refers to the transfusion of large volume of blood products over a short period of time to a patient who has severe or uncontrolled haemorrhage. MTPs describe an empirical treatment that optimizes management of resuscitation and correction of coagulopathy arising from severe haemorrhage. In adults, several definitions of MT exist based on the volume of the blood products transfused and also the time frames over which these transfusions occurred. 1 -3 The three most
The above definitions are only applicable for adult patients. Because of the age and weight variability in determining TBV in children (Table 2) , paediatric patients require separate MT definitions. Recently, Diab and colleagues 4 suggested the following definition of MT in the paediatric population:
(i) transfusion of .100% TBV within 24 h, (ii) transfusion support to replace ongoing haemorrhage of .10% TBV min 21 , and (iii) replacement of .50% TBV by blood products within 3 h.
Epidemiology of MT
The need for MT occurs in a variety of clinical settings, such as trauma, obstetrics, and major surgery. Trauma-related mortality is the fourth leading cause of death in the USA, and according to the Centers for Disease Control and Prevention, unintentional injury accounted for more than 120 000 deaths in 2010. 6 About 40% of trauma-related mortality is due to uncontrolled bleeding. It has been estimated that among the injured patients admitted to trauma centres, up to 10% of military and up to 5% of civilian patients require MT. 7 8 In general, injury severity and transfusion requirement are associated with mortality. Most (99%) of the patients receiving ,10 RBC units within the first 24 h survived, whereas only 60% of patients who received .10 RBC units within the first 24 h survived. 9 Obstetrical haemorrhage is another common cause of MTmassive haemorrhage is the most common cause of shock in obstetric patients and is the number one cause of maternal mortality worldwide. 10 Other causes of MT include gastrointestinal haemorrhage and major surgeries, such as cardiac, spinal, and liver surgery, and liver and multivisceral transplantation.
Pathophysiological changes as a result of massive haemorrhage and transfusion
The majority of the current understanding regarding the haemostasis and pathophysiological changes that occur during massive haemorrhage and the resultant MT are derived from animal and adult trauma patient studies. 4 11-13 The haemostatic defects in patients undergoing massive haemorrhage are dynamic and have multifactorial pathogenesis that relate to early trauma-induced coagulopathy (ETIC, also termed acute coagulopathy of trauma), transfusion of blood products, and infusion of crystalloids. 14 Historically, ETIC was attributed to crystalloid and RBC transfusion without administration of platelets, plasma, or both. However, subsequent studies in both adult and paediatric trauma patients demonstrated that ETIC was present in 24%, and up to 56% in severely injured patients, usually within 30 min of injury, even before receiving RBC and fluid resuscitation. 11 15 -18 The presence of ETIC correlates with poor clinical outcomes independent of the severity of injury. 11 16 -18 ETIC is associated with systemic anticoagulation and hyperfibrinolysis. In brief, tissue injury from trauma or surgery releases tissue factor, locally and subsequently systematically, which activates coagulation pathways. This initiation results in massive consumptive coagulopathy leading to a consumptive disseminated intravascular coagulation-like syndrome, which is most commonly seen in patients with severe head injury or extensive muscle damage. 19 20 Furthermore, hypoperfusion from massive haemorrhaging leads to thrombomodulin expression on endothelial cells. 11 21 Thrombin-thrombomodulin complex then activates protein C, which further limits coagulation by inhibiting activated factors V and VIII and enhancing fibrinolysis by depleting plasminogen activator inhibitor-1 (PAI-1) and accelerating plasmin formation. The diversion of thrombin from cleaving fibrinogen (for clot formation) to binding to thrombomodulin also reduces activation of thrombin-activatable fibrinolysis inhibitor (TAFI), which further leads to hyperfibrinolysis. The end result of these complex mechanisms is characterized by early coagulopathy due to systemic anticoagulation and hyperfibrinolysis. 22 23 In obstetric haemorrhage, hyperfibrinolysis is a prominent sign, both due to the above mechanism and to uterine atony, placental abruption, and accretism. 24 In addition to ETICand hyperfibrinolysis, further coagulopathy results from infusion of crystalloids, blood products, and severe anaemia. Massive haemorrhage leads to anaemia, which reduces primary haemostasis by impairing platelet adhesion and aggregation. The administration of RBC units without additional clotting factors or platelets during MTresults in further impairment of haemostasis from both haemodilution (dilutional coagulopathy and thrombocytopenia) and metabolic derangement (acidosis and hypocalcaemia from citrate in storage solution, and hypothermia from refrigeration). 25 -27 Acidosis and hypocalcaemia are detrimental to normal haemostasis. 27 Furthermore, hypothermia is associated with impairment of both platelet and coagulation factor activity. 4 All of these 'exogenous' factors contribute to the vicious cycle of progressive coagulopathy due to the 'lethal triad' of refractory coagulopathy, progressive hypothermia, and persistent metabolic acidosis (Fig. 1) . 4 
Predicting MT
Early recognition and prompt treatment results in improved outcomes in massively bleeding patients. In many situations, it is unclear which bleeding patient will need MT. Models have been developed using both clinical and laboratory parameters to predict who would need MT in trauma patients; 28 -35 however, none of them are a perfect tool. 36 For example, the Trauma Associated Severe Hemorrhage (TASH)-score incorporated seven clinical and laboratory variables (haemoglobin, base excess, systolic arterial pressure, heart rate, presence of free intra-abdominal fluid and/or complex fractures, and gender) into a composite score to predict the need for MT (defined in the study as administration of 10 or more RBC units within 24 h). 34 Nonetheless, Nunez and colleagues 35 demonstrated that simple and rapidly available parameters, such as the presence of penetrating trauma, systolic arterial pressure ,90 mm Hg, heart rate .120 beats min 21 , and a positive focused abdominal sonography for trauma, appears to be as good as other more complex scoring systems to predict MT. If any two of the above four parameters are positive, the patient is likely going to require MT.
Clinical management in MT
In patients requiring MT, it is critical to maintain adequate blood flow and arterial pressure to maintain tissue oxygenation to vital organs. In the past, patients who are bleeding profusely, especially trauma patients, were initially given colloid or crystalloid fluid. Blood products were administered after 2 litre of fluid resuscitation, usually guided by laboratory results to keep haemoglobin .10 g dl 21 , platelet count .50 000 ml 21 , and INR ≤1.5. Using these guidelines, blood loss continued because of delay in laboratory turnaround time and dilutional coagulopathy. Mathematical consideration of resuscitation, studies highlighting increased morbidity and mortality with crystalloid use, recent military experiences, and better understanding the pathophysiology of ETIC has led to early use of RBCs, plasma, and platelets and reduced crystalloid use in resuscitation. Mathematical analysis of the available current component therapies in the USA suggested that when administering RBC, plasma, and platelets in a 1:1:1 ratio, this 645 ml product has a haematocrit of 29%, coagulation factor activity of 65%, and a platelet count of 90 000 ml 21 . 37 In addition, if storage defects are taken into account, then this mixed product would have a haematocrit of 26%, coagulation factor activity of 40-50%, and platelet count of 90 000 ml 21 . 37 Furthermore, any attempt to increase the concentration of one component would lead to dilution of the other two. The administration of RBC:plasma:platelets at 1:1:1 ratio was first proposed by the US military and subsequently supported by military and then civilian studies. The rationale for the 1:1:1 ratio is that it more closely resembles whole blood, which would help to treat and prevent ETIC. A retrospective review of patients receiving MTat a US combat hospital demonstrated reduced mortality from 66% to 19% when the RBC:plasma ratio decreased from 8:1 to 2:1. 38 Then, Johansson and Stensballe 39 demonstrated that high plasma and platelet-to-RBC ratios improved survival in military traumatically injured patients with MT. However, these studies, and multiple others, are retrospective, and are therefore affected by survival bias. Survival bias is the bias resulting from the fact that surviving patients are more likely to receive more plasma and platelets in relation to RBCs compared with nonsurviving patients because they lived long enough to receive those blood products. Thus, in June 2011, the Canadian National Advisory Committee on Blood and Blood Products determined that the retrospective evidence available at the time was insufficient to recommend a RBC:plasma:platelet transfusion ratio of 1:1:1 as the standard of care for MT in Canada. They also stated that subsequent retrospective studies would be unlikely to overcome survivorship bias and would not be able to make further contributions to the determination of the most effective ratio. 40 Recently, the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study examined the association between mortality rates in trauma patients and transfusion ratios; this cohort study demonstrated improved in-hospital mortality with RBC:plasma and RBC:platelet ratios ,2:1 in the first 6 h. 41 The follow-up Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial is a randomized trial to evaluate ratios, MTpatients receive either a 1:1:1 (higher ratio) or a 2:1:1 (lower ratio) RBC:plasma:platelet with primary outcome of survival, and also complications and length of hospital stay. The results of this study should further elucidate the optimal ratios of blood product administration during MT.
Massive transfusion protocols
One way to coordinate the care for patients requiring MT is to develop an institutional MTP to facilitate communication between different services (trauma, nursing, transfusion medicine, and other laboratories), avoid delay in clinical care, laboratory testing and blood product transfusion, and nursing care. MTP is a way to assure good patient care by having a standard protocol on specific actions to take for each service involved. MTPs have demonstrated improved patients survival and reduced rates of organ failure and post-trauma complications. 29 The development, implementation, and continuous improvement of an MTP require ongoing collaboration MTPs can include preparation and administration of blood products based on laboratory test results, predetermined transfusion packages [see Table 3 (adult MTPs) and Table 4 (paediatric MTPs), for examples), or integration of both. 42 Although the number and timing of blood component delivery, laboratory testing algorithms, and other aspects of the MTPs varies between institutions, most current MTPs use predetermined transfusion packages. 42 MTPs vary in their predetermined transfusion packages, but all include platelet and plasma units with RBC units (Table 3) . 43 -48 Furthermore, patients with obstetrical haemorrhage should also be monitored closely for fibrinogen level, because it has been shown that women with fibrinogen level .400 mg dl 21 did not develop post-partum haemorrhage. Similarly, data from neurology and cardiac surgery showed that there is increased bleeding tendency if the fibrinogen level is ,150 -200 mg dl 21 . 49 50 Moreover, a retrospective review from a US Army hospital demonstrated that increasing the ratio of fibrinogen:RBC is associated with improved survival to hospital discharge by decreasing death from bleeding. 51 Thus, monitoring fibrinogen level and/or early transfusion of fibrinogen concentrate or cryoprecipitate could be potentially beneficial. The military uses fresh whole blood when apheresis platelet products are not available. In the recent military experiences in Iraq and Afghanistan, whole blood transfusion compared with RBC, plasma, and apheresis platelet use reduced pulmonary and tissue oedema, which decreased the ventilation time and also allowed closure of the abdomen with minimal delay. 52 Furthermore, retrospective analysis suggested that patients who received both fresh whole blood and component therapy had better clinical outcomes compared with those who received only component therapy. 53 However, concern for transfusiontransmitted infections and transfusion-associated graft vs host disease remains. 54 55
Paediatric MTPs
The data on paediatric MTPs are limited, and thus practices vary significantly among institutions. 56 57 Owing to logistics, it is a challenge for hospitals that are not free-standing children's hospitals to have both adult and paediatric MTPs. In the majority of institutions, a single MTP is used for both adult and paediatric patients. 4 Two published studies on paediatric MTPs did not show improvement in mortality in the group receiving blood products according to the institutional MTP compared with the historical control 58 or the group receiving blood products at physician discretion (Table 4) . 59 Despite obtaining null results in both studies, probably due to small sample sizes, 58 59 it was suggested that implementation of MTP to increase the plasma:RBC ratio is feasible in paediatric patients. 58 
Considerations for MTP development
When developing an MTP, it is important that an institution establishes policies for emergency release and delivery of blood products. There should also be protocols for administration of D-positive RBCs to a D-negative or unknown patient, issuing ABO-incompatible plasma, and administration of antigenpositive or untested RBCs to a patient with the corresponding red cell alloantibody. It is also important to follow patient identification protocols in order to avoid ABO incompatible transfusion errors. In many trauma situations, there is excessive blood loss, and transfusion is needed before the ability to perform pretransfusion testing. In these cases, group O RBCs and AB plasma products should be given until the patient's blood type can be determined. Alternatively, it has been demonstrated that using group A plasma products in trauma patients needing emergency plasma transfusion due to limited supply of group AB plasma did not result in an increase in mortality or incidence of complications, such as haemolytic reaction. 60 It is important to obtain and test a patient sample as soon as possible after admission so that type-specific products can be administered when available. This helps to preserve the inventory of group O RBCs and AB plasma, and minimizing potential for ABO typing discrepancies when a patient has received multiple units 
Alternative medications included in MTP
Recombinant activated factor VII (rFVIIa) is approved by the US Food and Drug Administration to treat bleeding in patients with congenital factor VII deficiency and patients with haemophilia A or B who have inhibitors against factor VIII or IX, respectively. However, it has been used off-labelled in many settings involving MT. In several clinical trials in patients with trauma or undergoing surgery, rFVIIa has not been shown to improve clinical outcomes. 67 -69 Furthermore, rFVIIa has been associated with thrombotic risk. 70 71 Therefore, the risk and benefit of using rFVIIa in patients with MTare unclear currently. A few experts suggest that rFVIIa should be removed as an adjunctive therapy from an institutional MTP. 72 If a physician would like to use rFVIIa as an adjunctive therapy, it should be given as early as possible at a time when haemostasis has not been severely compromised. 73 Prothrombin complex concentrate (PCC) has been used to treat congenital coagulation disorders and for warfarin reversal in patients with active bleeding or undergoing urgent procedures. PCC contains factors II, VII, IX, and X, and proteins C and S, with variations in the amount of factors between different products; thus, it is important to know which PCC product is available at the institution. PCC can be three-factor, such as Profilnine SD (Grifols Biologicals, Los Angeles, CA, USA) (lacking factor VII), or four-factor, such as Kcentra (CSL Behring, King of Prussia, PA, USA). To date, there has not been any prospective randomized controlled trial to evaluate the efficacy and safety of PCC in massively bleeding patients. In addition, PCC might be associated with thromboembolic risk as shown in animal studies. 74 75 Hence, it is advisable to discuss the risks and benefits of using PCC as an adjunctive therapy in any institutionally MTP and it is recommended that PCC usage should be continually evaluated.
In several small prospective studies, fibrinogen concentrate has been shown to reduce peri-operative bleeding and transfusion requirement. 76 -79 Fibrinogen concentrates, in conjunction with PCC, also have been shown in a few prospective studies to decrease the transfusion requirements and mortality in trauma patients. 80 81 In the USA, fibrinogen concentrate (RiaSTAP, CSL Behring) is approved for the treatment of patients with congenital fibrinogen deficiency. It has not been approved to be used as an adjunctive therapy in patients requiring MT. Therefore, it is recommended to discuss the risk and benefit of using fibrinogen concentrate as part of the MTP in any institution (see Tanaka and colleagues, 82 this issue, for further discussion). Antifibrinolytic agents, such as tranexamic acid (TXA), were demonstrated to reduce mortality in trauma patients in both civilian 83 and military settings, 84 especially if given early in the resuscitation process (,3 h from injury to treatment, preferably within 1 h from injury). 85 In the military setting, the MATTERs study demonstrated that although patients receiving TXA were more severely injured, mortality in the TXA group was lower than in the group not receiving TXA. 84 Moreover, TXA was shown to be a cost-effective therapy in all low-, middle-, and high-income countries using data from the randomized controlled CRASH-2 trial done in a civilian population. 86 It has also been suggested that TXA reduces blood loss at the time of Caesarean section and the risk of progression to severe postpartum haemorrhage. 87 88 A randomized controlled trial is currently ongoing to access the effect of TXA in treating postpartum haemorrhage. Smaller studies also showed that TXA reduced blood loss in paediatric patients undergoing cardiac 89 or scoliosis surgery. 90 Therefore, it is recommended that TXA should be part of the early resuscitation process.
Laboratory monitoring during MTP
MTP requires adequate laboratory support to oxygen-carrying capacity, haemostasis, and metabolic status in order to address and correct abnormalities. In addition, laboratory results can be used retrospectively to assess the need for MTP adjustment. For example, if all patients have low fibrinogen values upon intensive care unit admission, increased cryoprecipitate or fibrinogen concentrate use is indicated during MTP. A metabolic panel should be used to monitor metabolic abnormalities during MT, such as hyperkalaemia and hypocalcaemia. Point-of-care arterial blood gases measurement is helpful in monitoring oxygenation.
Monitoring haemostasis in patients with MT is challenging because there is no validated coagulation assay that can detect accurately the coagulopathies in massively bleeding patients in a timely manner. Conventional coagulation assays, such as PT, aPTT, and fibrinogen levels, are likely not available in real-time fashion. In addition, these tests do not detect some haemostatic abnormalities, such as platelet dysfunction, hyperfibrinolysis, and factor XIII deficiency. They also do not quantify the relative contribution of pro-coagulant and anti-coagulant factors. 91 92 Although these conventional coagulation assays do not predict the future need for MTP and have limited utility to direct ongoing blood component therapy in real time because of slow turnaround times, 93 they should be ordered and retrospectively reviewed to help in correcting any abnormalities occurring during the resuscitation and to continuously improve the institutional MTP. Recently, it has been suggested that point-of-care haemostasis assays, such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM), might be better at assessing coagulopathy in patients requiring MT. 94 These assays offer clinicians a graphic representation of the coagulation process (Fig. 2) . In addition, the parameters obtained from TEG/ ROTEM could provide a quantitative measure of individual components of the haemostatic process in adult patients (Table 5) . Hence, the use of TEG/ROTEM can provide information to guide blood component therapies in a more timely manner. 94 There are several advantages of using TEG/ROTEM. 4 First, the turnaround time for these assays is shorter compared with conventional assays (15-30 min); thus, they can be used in Table 5 TEG/ROTEM parameters, interpretations, and management of haemostatic abnormalities. 4 Modified from Table 3 there is no evidence that TEG/ROTEM reduced the morbidity and mortality in MT patients. 101 There is no universal agreement on the use of TEG/ROTEM to monitor and direct component therapy in patients with MT.
Complications from MT
Besides the risk of transfusion reactions that occur with single unit transfusions, patients with MT are at risk of other adverse events due to large transfusion volumes, such as hypocalcaemia and acidosis due to citrate and hypothermia due to cold storage (Table 6 ). 4 The patient should be monitored closely for these complications because they might contribute further to coagulopathy. Paediatric patients, patients with preexisting cardiac, hepatic, and renal disease, or older patients are more at risk for having these complications. Another potential risk is the use of stored RBCs, although no randomized controlled trial has demonstrated an association Table 6 Complications from MT. 4 Modified from Table 1 Instructions and/or protocols on how to use rapid infuser must be followed of red cell storage age and patient outcome. A recent meta-analysis investigating the effect of storage lesions of RBCs suggested that using older stored RBC units was associated with increased mortality. 102 However, the majority of data in this meta-analysis was from retrospective observational studies. A recent large randomized controlled trial done in premature, very low-birth-weight infants (the ARIPI trial) did not find an association between using fresh RBCs and improved mortality. 103 Several other trials (such as the RECESS trial) are ongoing at the time of writing to investigate the storage effect of RBCs, on clinical outcome of transfusion (see Cohen and Matot, 104 this issue, for further discussion).
Conclusions
For optimal management of massively bleeding patients, effective communication between the transfusion and other laboratory medicine services and clinical teams is essential. It is important for the transfusion medicine service to prepare necessary blood products while managing the blood inventory. A well-defined MTP is a valuable tool for institutions, especially for institutions that have an active trauma, high-risk pregnancy, cardiac surgery, and/or transplantation service, as it can delineate how blood products are ordered, prepared, and delivered, determine laboratory algorithms to use as transfusion guidelines, and facilitate communication between the transfusion service and clinical team. Instructions regarding nursing care and specific duties for other allied health personnel should be in the protocol. Early transfusion of platelets, plasma, and RBCs to trauma patients in a ratio approaching 1:1:1 might be beneficial in reducing mortality and improving patient outcome; however, further prospective randomized clinical trials will be useful in determining the optimal ratio. TXA improved survival in several randomized controlled trials in patients with MT, and thus, should be used during the resuscitation process. There is also evidence that other medical interventions or products, such as TEG/ROTEM and PCC, might improve patient outcome when used in combination with an MTP. The guidelines for MTP have been changing in recent years with the completion of several studies, and likely will continue to evolve as future studies are completed. These will further clarify the ideal ratios of blood products, patientspecific modifications, and other measures that should be taken in the management of massively bleeding patients.
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